Takeda Pharmaceutical (TKPHF) Net Income (2017 - 2026)

Takeda Pharmaceutical's Net Income history runs 10 years deep, the most recent figure standing at -$154.7 million for Q1 2026.

• In Q1 2026, Net Income fell 105.51% year-over-year to -$154.7 million; the TTM figure through Mar 2026 stood at $11.3 billion (down 10.61% YoY), while the FY2026 annual figure was $1.3 billion, up 79.69% from the prior year.
• Net Income was -$154.7 million for Q1 2026 at Takeda Pharmaceutical, down from $1.4 billion in the prior quarter.
• In the past five years, Net Income ranged from a high of $7.5 billion in Q3 2025 to a low of -$154.7 million in Q1 2026.
• Historically, Net Income has averaged $2.2 billion across 5 years, with a median of $1.6 billion in 2023.
• The sharpest annual moves came in 2023 and 2026: Net Income jumped 360.67% in 2023, then plunged 105.51% in 2026.
• A 5-year view of Net Income shows it stood at $673.6 million in 2022, then jumped by 161.65% to $1.8 billion in 2023, then retreated by 25.02% to $1.3 billion in 2024, then advanced by 3.75% to $1.4 billion in 2025, then tumbled by 111.28% to -$154.7 million in 2026.
• The last three Net Income figures came in at -$154.7 million (Q1 2026), $1.4 billion (Q4 2025), and $7.5 billion (Q3 2025), per Business Quant data.